GlassScriptPhysician profile
Bryan T Arnette
NPI 1023047768
$9,378.69
in general payments reported to CMS, 2019-2025
42 companies · $1,322 in 2025
The $1,322 reported for 2025 was more than what 90% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,122 · 2020: $1,316 · 2021: $1,762 · 2022: $1,170 · 2023: $1,085 · 2024: $1,601 · 2025: $1,322.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,008.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,008.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,227.13 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Abbvie INC. | $907.82 | 2020-2025 | Vraylar, Qulipta, Ubrelvy |
| Lilly USA, LLC | $878.13 | 2019-2025 | Mounjaro, Zepbound, Trulicity |
| Novo Nordisk INC | $807.99 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Glaxosmithkline, LLC. | $720.53 | 2019-2025 | Trelegy Ellipta, Arexvy |
| Pfizer INC. | $463.97 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $407.98 | 2019-2022 | |
| Amgen INC. | $322.66 | 2019-2023 | Repatha |
| Bayer Healthcare Pharmaceuticals INC. | $299.51 | 2021-2025 | |
| Abbott Laboratories | $274.53 | 2021-2025 | Freestyle Libre 3 |
| Esperion Therapeutics, INC. | $272.29 | 2020-2025 | Nexletol |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $268.93 | 2019-2025 | Xifaxan |
| Sanofi-Aventis U.S. LLC | $222.85 | 2019-2023 | |
| Novartis Pharmaceuticals Corporation | $210.32 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $209.41 | 2019-2025 | Trintellix |
Show all 42 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $193.31 | 2019-2023 | Verquvo, Belsomra |
| E.R. Squibb & Sons, L.L.C. | $192.48 | 2020-2025 | Eliquis, Camzyos |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $189.29 | 2024-2025 | Caplyta |
| Amarin Pharma, INC. | $189.11 | 2019-2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $165.34 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $125.31 | 2020-2024 | Jardiance |
| Astellas Pharma US INC | $105.79 | 2019-2025 | Veozah, Myrbetriq |
| Allergan, INC. | $90.60 | 2019-2020 | |
| Idorsia Pharmaceuticals US INC | $84.59 | 2022-2024 | Quviviq |
| Antares Pharma, INC. | $82.74 | 2021-2023 | Xyosted, Tlando, Nocdurna |
| Inogen, INC. | $66.24 | 2023-2025 | Inogen At Home Stationary Concentrator |
| Eisai INC. | $46.02 | 2021 | |
| Vanda Pharmaceuticals INC. | $43.68 | 2020-2021 | |
| Axsome Therapeutics, INC. | $37.28 | 2025 | Auvelity |
| Lundbeck LLC | $35.38 | 2021-2024 | Vyepti |
| Dexcom, INC. | $34.13 | 2024 | Dexcom G6 Transmitter |
| Phathom Pharmaceuticals, INC. | $26.19 | 2024 | Voquezna |
| Kowa Pharmaceuticals America, INC. | $24.39 | 2019 | |
| Medtronic, INC. | $23.08 | 2025 | Intellis Adaptivestim |
| Nestle Healthcare Nutrition INC. | $20.60 | 2021 | |
| Corium, LLC | $19.77 | 2023 | Adlarity |
| Sumitomo Pharma America, INC. | $17.96 | 2023 | Gemtesa |
| Exact Sciences Corporation | $17.59 | 2025 | Cologuard Collection Kit |
| Biohaven Pharmaceuticals, INC. | $14.72 | 2021 | |
| Horizon Therapeutics Plc | $13.64 | 2021 | |
| Mylan Specialty L.P. | $13.63 | 2023 | Yupelri |
| Teva Pharmaceuticals USA, INC. | $11.78 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bryan Arnette listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.